ALK rearrangement / fusion

ALK gene rearrangements (most often EML4-ALK) detected by FISH, immunohistochemistry or sequencing; used as a predictive marker for ALK inhibitors in non-small cell lung cancer and some lymphomas.

CI-BIO-00000013ALK graph →NCIt C142135 Tumor-agnostic · 3 approval rows

Also calledALK-positive · ALK rearrangement · EML4-ALK · ALK fusion

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (3)

Entrectinib EU EMA · Jul 31, 2020 · drug in derived setRegulatory approved
Entrectinib US FDA · Oct 20, 2023 · drug in derived setRegulatory approved
Entrectinib US FDA · Aug 15, 2019 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (20)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Lung Non-Small Cell Carcinoma	80	80	—	—	9 / 12 / 23 / 35 / 1
Neuroblastoma	18	18	—	—	0 / 0 / 6 / 12 / 0
Malignant Neoplasm	10	10	—

Derived

Drugs with predictive evidence (16)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
CrizotinibSmall Molecule	73	45	28	A	45 / 52	Anaplastic Large Cell Lymphoma, Colorectal Adenocarcinoma, Cutaneous Melanoma, Diffuse Large B-Cell Lymphoma +8
AlectinibSmall Molecule	23	13	10	A	14 / 17	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Neoplasm, Neuroblastoma +3
CeritinibSmall Molecule	18	15	3	A	21 / 5	Colon Adenocarcinoma, Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Neoplasm +1
LorlatinibSmall Molecule	10	7	3	B	10 / 7	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Neuroblastoma, Pleural Malignant Mesothelioma
ALK Inhibitor TAE684	9	7	2	D	7 / 3	Diffuse Large B-Cell Lymphoma, Lung Non-Small Cell Carcinoma, Neuroblastoma
BrigatinibSmall Molecule	6	5	1	A	7 / 2	Lung Non-Small Cell Carcinoma, Malignant Neoplasm, Neuroblastoma
EntrectinibSmall Molecule	5	5	—	B	4 / 0	Inflammatory Myofibroblastic Tumor, Malignant Colorectal Neoplasm, Malignant Neoplasm, Mucosal Melanoma +1
AlvespimycinSmall Molecule	3	3	—	D	2 / 0	Lung Non-Small Cell Carcinoma
TanespimycinSmall Molecule	2	2	—	D	4 / 0	Lung Non-Small Cell Carcinoma
Retaspimycin HydrochlorideSmall Molecule	2	2	—	C	2 / 0	Lung Non-Small Cell Carcinoma
LuminespibSmall Molecule	1	—	1	C	0 / 2	Lung Non-Small Cell Carcinoma
2,4-pyrimidinediamine	1	1	—	D	1 / 0	Lung Non-Small Cell Carcinoma
AZD3463	1	1	—	D	1 / 0	Neuroblastoma
ErlotinibSmall Molecule	1	—	1	C	0 / 1	Lung Acinar Adenocarcinoma
PemetrexedSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
WHI-P154	1	1	—	D	1 / 0	Lung Non-Small Cell Carcinoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (148)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 101–148 of 148 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ALK C1156Y + ALK L1198F + ALK Fusion1
Lorlatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Resistance	4	accepted	EID843 Case report of a patient with metastatic ALK-rearranged NSCLC. After developing resistance to first and second line ALK inhibitors mediated by a C1156Y mutation, the patient had a partial response wit… (full text at CIViC) PMID 26698910 · Shaw et al., 2016 · Open in CIViC	civic
ALK Fusion3
Lorlatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID1332 EML4-ALK variant 1 containing H-3122 NSCLC cells were treated with second generation ALK inhibitor PF-06463922. PF-06463922 was 125x more potent at reducing cell viability than crizotinib. Control neu… (full text at CIViC) PMID 26554404 · Infarinato et al., 2016 · Open in CIViC	civic
WHI-P154	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	5	accepted	EID1188 A retroviral cDNA expression library was constructed using a lung adenocarcinoma specimen from a 67 year old NSCLC patient, and transfected into mouse 3T3 fibroblasts which were assessed for transform… (full text at CIViC) PMID 17625570 · Soda et al., 2007 · Open in CIViC	civic
Alectinib	Pleural Malignant Mesothelioma
ALK Fusion7
Pemetrexed	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID945 Among 95 patients with NSCLC in this study, 15 had an ALK translocation. ORR of these patients compared to EGFR mutated or wild-type tumors was superior (46.7 versus 4.7 versus 16.2%, p = 0.001). TYMS… (full text at CIViC) PMID 21642865 · Lee et al., 2011 · Open in CIViC	civic
Retaspimycin Hydrochloride	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID1202 In this study, heavily pretreated advanced NSCLC patients with various molecular tumor makeup were treated with Hsp90 inhibitor IPI-504 to assess overall response rate. The study did not reach the tar… (full text at CIViC) PMID 20940188 · Sequist et al., 2010 · Open in CIViC	civic
Crizotinib	Malignant Breast Neoplasm
ALK T1151dup + ALK Fusion1
Tanespimycin	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID1349 Ba/F3 cells transduced with EML4-ALK 1151 insT were treated with 17-AAG producing an IC50 value of 44.5 nM, which was 0.4 times that reported for EML4-ALK wildtype in Ba/F3, indicating possible increa… (full text at CIViC) PMID 22277784 · Katayama et al., 2012 · Open in CIViC	civic
ALK G1202R + ALK Fusion3
Tanespimycin	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID1352 The G1202R ALK mutation was found in a crizotinib-resistant ALK-rearranged NSCLC, and the mutant ALK fusion was further characterized in Ba/F3 cells. EML4-ALK variant 1 with G1202R mutation was expres… (full text at CIViC) PMID 22277784 · Katayama et al., 2012 · Open in CIViC	civic
Alectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID1350 Ba/F3 cell line expressing EML4-ALK variant 3 with G1202R ALK mutation was assessed for alectinib sensitivity and IC50 for survival of 868 nM was reported, which was 64.4x higher than the IC50 reporte… (full text at CIViC) PMID 25727400 · Fontana et al., 2015 · Open in CIViC	civic
Brigatinib	Malignant NeoplasmALIAS
ALK Fusion1
Entrectinib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID7481 A patient with colorectal cancer harboring a CAD-ALK fusion gene was treated with the ALK inhibitor entrectinib, resulting in durable objective tumor response. A CT scan four weeks after treatment ini… (full text at CIViC) PMID 26633560 · Amatu et al., 2015 · Open in CIViC	civic
ALK G1269A + ALK Fusion3
Alectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID1354 EML4-ALK with ALK G1269A mutation was tested for sensitivity to alectinib using Ba/F3 cells. In Ba/F3 cells with ectopic EML4-ALK variant 1 G1269A, IC50 of 84 nM was reported with alectinib, which was… (full text at CIViC) PMID 25727400 · Fontana et al., 2015 · Open in CIViC	civic
Brigatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1353 EML4-ALK with ALK G1269A has been seen in crizotinib resistant NSCLC, and this mutation was tested for Brigatinib sensitivity via ectopic expression in Ba/F3 cells, where half maximal inhibitory conce… (full text at CIViC) PMID 25727400 · Fontana et al., 2015 · Open in CIViC	civic
Ceritinib	Malignant NeoplasmALIAS
ALK Fusion + ROS1 FusionALK ROS11
Crizotinib	Malignant NeoplasmALIAS	Predictive	B	Supports Sensitivity Response	2	accepted	EID11671 This clinical study was conducted on patients harboring either ROS1 or ALK rearrangements, and were treated with Crizotinib. The two sub-protocols F(ALK rearrangements) and G(ROS1 rearrangements) had … (full text at CIViC) PMID 35233056 · Mansfield et al., 2022 · Open in CIViC	civic
ALK e6::e201
Crizotinib	Malignant NeoplasmALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID1245 This case study presented a 53-year-old never-smoker with a poorly differentiated malignant neoplasm. Morphology and immunohistochemistry were unable to establish the primary tumor site. Right upper e… (full text at CIViC) PMID 25408655 · Chung et al., 2014 · Open in CIViC	civic
ALK F1245C + ALK Fusion1
Crizotinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	2	accepted	EID1337 A Ba/F3 cell line expressing EML4-ALK variant 1 was created, and then exposed to the DNA modifying agent ENU. Cells were subsequently cultured in 96 well plates at increasing concentrations of crizoti… (full text at CIViC) PMID 22034911 · Zhang et al., 2011 · Open in CIViC	civic
ALK Fusion1
Crizotinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1356 In Ba/F3 cells, crizotinib sensitivty of the NPM-ALK variant was compared to crizotinib sensitivity of EML4-ALK variant 3. 50% of maximal inhibitory concentration for NPM-ALK was 42 nM, which was appr… (full text at CIViC) PMID 25727400 · Fontana et al., 2015 · Open in CIViC	civic
ALK Alternative Transcript (ATI)1
Entrectinib	Mucosal Melanoma	Predictive	C	Does Not Support Sensitivity Response	4	accepted	EID7421 ALK expression was analyzed in 45 melanoma patient-derived xenografts (PDXs), with 11/45 showing ALK expression. Four PDX tumours had only wild-type ALK expression, four had only ALK alternative trans… (full text at CIViC) PMID 29054983 · Couts et al., 2018 · Open in CIViC	civic
ALK F1174L7
Alectinib	Neuroblastoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID37 CH5424802 (Alectinib) is effective in inhibiting the activity of the F1174L ALK mutant in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells. PMID 21575866 · Sakamoto et al., 2011 · Open in CIViC	civic
ALK Inhibitor TAE684	Neuroblastoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID142 SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition. PMID 18923525 · George et al., 2008 · Open in CIViC	civic
AZD3463	Neuroblastoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID1327 The SH-SY5Y neuroblastoma cell line containing the F1174L ALK mutation was found to undergo cell death when treated with the ALK/IGF1R inhibitor AZD3463. These cells were more sensitive than other neu…
ALK R1275Q6
ALK Inhibitor TAE684	Neuroblastoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID39 This study identified previously unknown mutations in the ALK gene in 8% (7/93) of primary neuroblastomas and neuroblastoma cell lines (6/30). R1275Q was found in the germline of one patient sample an… (full text at CIViC) PMID 18923525 · George et al., 2008 · Open in CIViC	civic
〃	Neuroblastoma	Predictive	D	Supports Resistance	3	accepted	EID48 The SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684. PMID 18923525 · George et al., 2008 · Open in CIViC	civic
Crizotinib	Neuroblastoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID1269 This Phase I study of crizotinib involved a cohort of pediatric neuroblastoma patients between ages 12 months and 22 years. In 11 patients with characterized ALK mutations, 4 had R1275Q mutations, and…
ALK Exon 4-11 Deletion1
Brigatinib	Neuroblastoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID1336 The MYCN amplification positive relapsed neuroblastoma-derived cell line CLB-BAR contains the driver ALK DEL 11-14 mutation, which removes extracellular domain exons 4 through 11. Brigatinib treatment… (full text at CIViC) PMID 27049722 · Siaw et al., 2016 · Open in CIViC	civic
ALK I1171T1
Ceritinib	Neuroblastoma	Predictive	C	Supports Sensitivity Response	4	accepted	EID9404 This case reports a 16-mo-old boy with metastatic neuroblastoma (stage M). Genomic analysis of a diagnostic biopsy of the tumor and matched normal identified two germline mutations in FANCA and somati… (full text at CIViC) PMID 29907598 · Guan et al., 2018 · Open in CIViC	civic
ALK F1245C2
Crizotinib	Neuroblastoma	Predictive	C	Supports Resistance	3	accepted	EID1333 A participant in Children's Oncology Group (COG) study AVDL0912 with measurable neuroblastoma mutated at ALK F1245C was administered crizotinib at 100mg twice daily. The patient showed progressive di… (full text at CIViC) PMID 23598171 · Mossé et al., 2013 · Open in CIViC	civic
Lorlatinib	Neuroblastoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID1330 Patient derived xenografts of neuroblastoma Felix cells with F1245C ALK mutation in CB17 SCID mice showed growth inhibition with crizotinib treatment over control, and mice had improved duration of ev… (full text at CIViC) PMID 26554404 · Infarinato et al., 2016 · Open in CIViC	civic
ALK F1245V1
Entrectinib	Neuroblastoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID2987 Clinical trial of entrectinib in patients with ALK/ROS/TRK altered tumors. One patient with an ALK F1245V-mutant neuroblastoma achieved a durable, confirmed partial response (PR) lasting 8.3 months. T… (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC	civic
ALK Fusion1
Alectinib	Pancreatic Acinar Cell CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID10327 Case report of a 62-year old male patient diagnosed with pancreatic acinar cell carcinoma. Liver metastases were diagnosed and treatment was started with gemcitabine plus nab-paclitaxel regimen. After… (full text at CIViC) PMID 35005993 · Gaule et al., 2022 · Open in CIViC	civic
ALK I1171N + ALK L1196M + ALK Fusion2
Alectinib	Pleural Malignant MesotheliomaALIAS	Predictive	C	Supports Resistance	4	accepted	EID11115 A 33 year old male with no smoking history or known exposure to asbestos was diagnosed with malignant pleural mesothelioma (MPM). EML4::ALK was found using a panel of 520 genes in NGS, and the patient… (full text at CIViC) PMID 32600123 · Hu et al., 2020 · Open in CIViC	civic
Lorlatinib	Pleural Malignant MesotheliomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID11113 This case report describes a 33 year-old non-smoker with no known exposure to asbestos who was diagnosed with stage IIIB malignant pleural mesothelioma. Panel next generation sequencing (NGS) of 520 g… (full text at CIViC) PMID 32600123 · Hu et al., 2020 · Open in CIViC	civic
ALK G1202R + ALK I1171N + ALK L1196M + ALK Fusion1
Lorlatinib	Pleural Malignant MesotheliomaALIAS	Predictive	C	Supports Resistance	3	accepted	EID11114 This case report describes a 33 year-old non-smoker with no known exposure to asbestos who was diagnosed with stage IIIB malignant pleural mesothelioma. Panel next generation sequencing (NGS) of 520 g… (full text at CIViC) PMID 32600123 · Hu et al., 2020 · Open in CIViC	civic
ALK e2::e201
Unspecified therapy	Renal Cell CarcinomaCURATED_BROADER	Predictive	E	Supports Sensitivity Response	3	accepted	EID1266 Adenocarcinoma cells were detected via urinary cytology in a 53 year old woman. Cancer morphology suggested papillary renal cell carcinoma (RCC), type 2A. EML4-ALK variant 5 was discovered in tumor t… (full text at CIViC) PMID 22252991 · Sugawara et al., 2012 · Open in CIViC	civic
ALK Exon 2-18 Deletion + TFCP2 FusionTFCP2 ALK1
Alectinib	Spindle Cell Rhabdomyosarcoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID12406 A 31 year old male initially thought to have a mandibular osteosarcoma that was resected and treated with adjuvant radiation and cisplatin-doxorubicin. He had a mandibular recurrence with multiple pul… (full text at CIViC) PMID 39302072 · Csizmok et al., 2024 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (178)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Entrectinib	US FDA	Tumor-agnostic	Adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase ( NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.accelerated	approved	Oct 20, 2023	openfda
Entrectinib	US FDA	Tumor-agnostic	Adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase ( NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.accelerated	approved	Aug 15, 2019	openfda

4 records matched on indication text only (drug not in the derived set). Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (227)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 105 recruiting · 85 active phase 3 · 868 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 201–227 of 227 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06694129	Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC	not yet recruiting	—	40	National Cancer Center, ChinaOTHER	0	Nov 19, 2024	clinicaltrials
NCT06690541	Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC(COMLORLA)	not yet recruiting	—	100	Peking University Cancer Hospital & InstituteOTHER	0	Nov 15, 2024	clinicaltrials
NCT04127110	Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients(ALKALINE)	active not recruiting	Phase 2	68	European Organisation for Research and Treatment of Cancer - EORTCNETWORK	7	Nov 5, 2024	clinicaltrials
NCT04322890	Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation(PIKACHU)	recruiting	Phase 2	6,000	Hunan Province Tumor HospitalOTHER	1	Oct 22, 2024	clinicaltrials
NCT05501665	Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer	recruiting	Phase 1 / Phase 2	25	Vanderbilt-Ingram Cancer CenterOTHER	1	Oct 17, 2024	clinicaltrials
NCT05487391	A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.	recruiting	Phase 3	632	Qilu Pharmaceutical Co., Ltd.INDUSTRY	1	Oct 15, 2024	clinicaltrials
NCT05014464	ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma(ATPase)	recruiting	Phase 2	90	Hunan Province Tumor HospitalOTHER	1	Sep 20, 2024	clinicaltrials
NCT05766800	Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer	recruiting	Phase 2	100	Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER	1	Sep 19, 2024	clinicaltrials
NCT06594874	A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors	not yet recruiting	Phase 1	350	Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY	1	Sep 19, 2024	clinicaltrials
NCT05015010	Alectinib in Neo-adjuvant Treatment of Stage III NSCLC(ALNEO)	active not recruiting	Phase 2	33	Gruppo Oncologico Italiano di Ricerca ClinicaOTHER	1	Aug 9, 2024	clinicaltrials
NCT06532149	ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer(EROS)	recruiting	—	80	Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER	1	Aug 9, 2024	clinicaltrials
NCT05159245	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs(FINPROVE)	recruiting	Phase 2	250	Helsinki University Central HospitalOTHER	1	Jul 15, 2024	clinicaltrials
NCT05525338	Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels(ADAPT ALEC)	recruiting	Phase 4	196	University Medical Center GroningenOTHER	2	May 13, 2024	clinicaltrials
NCT06380348	JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations	not yet recruiting	Phase 3	398	Shanghai JMT-Bio Inc.INDUSTRY	0	Apr 23, 2024	clinicaltrials
NCT06254599	A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC	not yet recruiting	Phase 3	255	Shouyao Holdings (Beijing) Co. LTDOTHER	1	Feb 12, 2024	clinicaltrials
NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)(DRUP)	recruiting	Phase 2	1,550	The Netherlands Cancer InstituteOTHER	1	Jan 24, 2024	clinicaltrials
NCT05011487	Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC(NOCE01)	recruiting	Phase 2	30	Sun Yat-sen UniversityOTHER	1	Jan 16, 2024	clinicaltrials
NCT06109402	Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer	not yet recruiting	Phase 2	160	Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER	1	Dec 19, 2023	clinicaltrials
NCT06001151	Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative(ACHELOUS)	recruiting	Phase 2	49	Qian ChuOTHER	1	Aug 21, 2023	clinicaltrials
NCT05990127	A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer	not yet recruiting	Phase 3	642	AkesoINDUSTRY	1	Aug 14, 2023	clinicaltrials
NCT05891080	Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial	not yet recruiting	Phase 2	124	Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER	0	Jun 6, 2023	clinicaltrials
NCT05800340	Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC	recruiting	Phase 2	30	Guangdong Provincial People's HospitalOTHER	1	Apr 5, 2023	clinicaltrials
NCT05725200	Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer(EVIDENT)	recruiting	Phase 2	40	Oslo University HospitalOTHER	1	Feb 21, 2023	clinicaltrials
NCT04762459	Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection(APEX)	enrolling by invitation	Phase 3	606	Chinese Academy of Medical SciencesOTHER	1	Feb 24, 2022	clinicaltrials
NCT05132985	Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma	not yet recruiting	Phase 2	45	Liaoning Cancer Hospital & InstituteOTHER	1	Dec 10, 2021	clinicaltrials
NCT05104788	A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer(NeoIpower)	recruiting	Phase 2	27	Peking University Cancer Hospital & InstituteOTHER	1	Nov 3, 2021	clinicaltrials
NCT04153734	Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC(Evolution)	not yet recruiting	Phase 2	21	Kobe Minimally Invasive Cancer CenterOTHER	0	Nov 6, 2019	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (3)

Associated cancers (20)

Drugs with predictive evidence (16)

Predictive evidence items (148)

Approvals mentioning the linked drugs (178)

Active trials (227)

Linked publications (82)